We are investigating experimental medications for both Non-small cell lung cancer (NSCLC) and Small cell lung cancer (SCLC)
Non-small cell lung cancer (NSCLC) accounts for about 85–90% of Lung Cancer diagnoses, while Small cell lung cancer (SCLC) is composed of 10-15% of Lung Cancer diagnoses. These two types of cancer differ in how they grow and how they spread.
Answer a few questions below to see if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Get updates on lung cancer clinical trials